Overactive Bladder – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Overactive Bladder – Pipeline Review, H1 2018’, provides an overview of the Overactive Bladder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Overactive Bladder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Overactive Bladder

– The report reviews pipeline therapeutics for Overactive Bladder by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Overactive Bladder therapeutics and enlists all their major and minor projects

– The report assesses Overactive Bladder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Overactive Bladder

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

Dompe Farmaceutici SpA

Dong-A ST Co Ltd

FemmePharma Global Healthcare Inc

Hanmi Pharmaceuticals Co Ltd

Hydra Biosciences Inc

Ion Channel Innovations LLC

Ipsen SA

Juniper Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Lipella Pharmaceuticals Inc

Medy-Tox Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

Mylan NV

Pfizer Inc

Recordati SpA

Taiho Pharmaceutical Co Ltd

Taris Biomedical LLC

TheraVida Inc

Toray Industries Inc

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overactive Bladder Overview

Overactive Bladder Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Overactive Bladder Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Overactive Bladder Companies Involved in Therapeutics Development

Allergan Plc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

Dompe Farmaceutici SpA

Dong-A ST Co Ltd

FemmePharma Global Healthcare Inc

Hanmi Pharmaceuticals Co Ltd

Hydra Biosciences Inc

Ion Channel Innovations LLC

Ipsen SA

Juniper Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Lipella Pharmaceuticals Inc

Medy-Tox Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

Mylan NV

Pfizer Inc

Recordati SpA

Taiho Pharmaceutical Co Ltd

Taris Biomedical LLC

TheraVida Inc

Toray Industries Inc

XuanZhu Pharma Co Ltd

Overactive Bladder Drug Profiles

(mirabegron + solifenacin succinate) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abobotulinumtoxinA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AK-14 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-8010 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFL-23448 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fesoterodine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fesoterodine fumarate ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICE-3682 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPR-2579 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirabegron ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivobotulinumtoxin A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OP-687 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize PACAP Receptor for Anxiety, Overactive Bladder and Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pVAX-hSlo Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0438 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Overactive Bladder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize EP1 Receptor for Overactive Bladder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize PTGER1 for Overactive Bladder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solabegron Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solabegron MR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solifenacin succinate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solifenacin succinate DR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAC-302 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THVD-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trospium chloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vibegron Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5849 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Overactive Bladder Dormant Projects

Overactive Bladder Discontinued Products

Overactive Bladder Product Development Milestones

Featured News & Press Releases

Mar 28, 2018: Urovant Sciences Initiates Phase 3 Clinical Program for Vibegron in Patients with Overactive Bladder

Mar 19, 2018: Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB)

Mar 09, 2018: Astellas Received Approval for Solifenacin Oral Suspension for Pediatric Patients in Europe

Feb 28, 2018: Urovant Sciences Announces Upcoming Presentations of Data from Phase 2b Trial of Vibegron in Patients with Overactive Bladder

Jan 17, 2018: Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA

Nov 06, 2017: UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel in Combination with BOTOX for the Treatment of Overactive Bladder

Sep 12, 2017: U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

Jul 19, 2017: Investigational New Drug Application for RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Submitted to FDA by Allergan

Jun 30, 2017: Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

Oct 27, 2016: Velicept Therapeutics Names Clarence Young, M.D., Chief Medical Officer

Oct 07, 2016: Astellas Filed Lawsuit against Patent Infringement of Myrbetriq in the United States

Oct 05, 2016: Velicept Therapeutics Announces FDA Acceptance of IND Application of Novel, Once-Daily Formulation of Solabegron for the Treatment of Overactive Bladder

Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver

May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego

Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Table 1: Number of Products under Development for Overactive Bladder, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Universities/Institutes, H1 2018

Table 5: Products under Development by Companies, H1 2018

Table 6: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 7: Products under Development by Universities/Institutes, H1 2018

Table 8: Number of Products by Stage and Target, H1 2018

Table 9: Number of Products by Stage and Mechanism of Action, H1 2018

Table 10: Number of Products by Stage and Route of Administration, H1 2018

Table 11: Number of Products by Stage and Molecule Type, H1 2018

Table 12: Overactive Bladder Pipeline by Allergan Plc, H1 2018

Table 13: Overactive Bladder Pipeline by Asahi Kasei Pharma Corp, H1 2018

Table 14: Overactive Bladder Pipeline by Astellas Pharma Inc, H1 2018

Table 15: Overactive Bladder Pipeline by Dompe Farmaceutici SpA, H1 2018

Table 16: Overactive Bladder Pipeline by Dong-A ST Co Ltd, H1 2018

Table 17: Overactive Bladder Pipeline by FemmePharma Global Healthcare Inc, H1 2018

Table 18: Overactive Bladder Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Table 19: Overactive Bladder Pipeline by Hydra Biosciences Inc, H1 2018

Table 20: Overactive Bladder Pipeline by Ion Channel Innovations LLC, H1 2018

Table 21: Overactive Bladder Pipeline by Ipsen SA, H1 2018

Table 22: Overactive Bladder Pipeline by Juniper Pharmaceuticals Inc, H1 2018

Table 23: Overactive Bladder Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Table 24: Overactive Bladder Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Table 25: Overactive Bladder Pipeline by Lipella Pharmaceuticals Inc, H1 2018

Table 26: Overactive Bladder Pipeline by Medy-Tox Inc, H1 2018

Table 27: Overactive Bladder Pipeline by Merck & Co Inc, H1 2018

Table 28: Overactive Bladder Pipeline by Mezzion Pharma Co Ltd, H1 2018

Table 29: Overactive Bladder Pipeline by Mylan NV, H1 2018

Table 30: Overactive Bladder Pipeline by Pfizer Inc, H1 2018

Table 31: Overactive Bladder Pipeline by Recordati SpA, H1 2018

Table 32: Overactive Bladder Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018

Table 33: Overactive Bladder Pipeline by Taris Biomedical LLC, H1 2018

Table 34: Overactive Bladder Pipeline by TheraVida Inc, H1 2018

Table 35: Overactive Bladder Pipeline by Toray Industries Inc, H1 2018

Table 36: Overactive Bladder Pipeline by XuanZhu Pharma Co Ltd, H1 2018

Table 37: Overactive Bladder Dormant Projects, H1 2018

Table 38: Overactive Bladder Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 39: Overactive Bladder Dormant Projects, H1 2018 (Contd..2), H1 2018

Table 40: Overactive Bladder Dormant Projects, H1 2018 (Contd..3), H1 2018

Table 41: Overactive Bladder Discontinued Products, H1 2018

List of Figures

List of Figures

Figure 1: Number of Products under Development for Overactive Bladder, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Top 10 Targets, H1 2018

Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Routes of Administration, H1 2018

Figure 9: Number of Products by Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports